Analysis of contraindications and risk groups for taking Pazopanib (Victor)

1. Overview of pazopanib

Pazopanib (Pazopanib) is an oral multi-target tyrosine kinase inhibitor (TKI) that mainly acts on vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and interferon-regulated receptor (c-KIT), which exert anti-tumor effects by inhibiting tumor angiogenesis and tumor cell proliferation. The drug is already approved to treat patients with advanced renal cell carcinoma and unresectable soft tissue sarcoma. Despite its remarkable efficacy, pazopanib may cause serious adverse reactions in some patients due to its wide range of targets. Therefore, contraindications and high-risk groups need to be strictly identified.

2. Main contraindications

1.Those who are allergic to pazopanib or drug ingredients

Patients who have experienced severe allergic reactions (such as dyspnea, urticaria, severe rash or shock) to pazopanib and its excipients or similar TKI drugs are prohibited from using this drug to avoid life-threatening risks.

2.Patients with severe liver dysfunction or active liver disease

Pazopanib can cause elevated liver enzymes and even liver damage, so it is contraindicated in patients with severe liver function abnormalities (Child-Pugh C) or active hepatitis. Patients with moderate liver function abnormalities need to be carefully evaluated before use and adjust the dose or increase the frequency of monitoring if necessary.

3.Pregnant and lactating women

Pazopanib may have teratogenic effects on the fetus and is therefore contraindicated in pregnant women. At the same time, lactating women should avoid taking medication or suspend breastfeeding to prevent the medication from affecting the baby's health through milk.

4.Patients with recent major surgery or trauma

Since pazopanib has an anti-angiogenic effect, which may delay wound healing and increase the risk of bleeding, it should be discontinued at least 2 weeks before surgery, and its use should be avoided until wound healing is stable after surgery.

5.Patients with active bleeding or high risk of bleeding

Pazopanib may increase the risk of bleeding, especially in patients with peptic tract ulcers, a history of cerebrovascular disease, thrombocytopenia, or those taking anticoagulants and should be used with caution or contraindicated to prevent serious bleeding events.

3. Analysis of high-risk groups

1.Patients with cardiovascular disease

Pazopanib can cause hypertension, heart failure, and prolongation of the QT interval, so patients with uncontrolled hypertension, a history of myocardial infarction, arrhythmias, or congestive heart failure are at high risk. Blood pressure and electrocardiogram should be evaluated before use, and regular follow-up should be carried out during treatment. Antihypertensive drugs or cardiac treatment plans should be adjusted if necessary.

2.Patients with renal insufficiency

Although pazopanib is mainly metabolized by the liver, patients with renal insufficiency have reduced metabolism and excretion capacity and increased drug exposure, which may aggravate toxic reactions, such as hypertension, proteinuria, or renal damage. Therefore, patients with renal insufficiency need to assess the risks before taking the drug and monitor closely.

3.Elderly patients

Older patients are more likely to suffer from liver and kidney toxicity, cardiovascular events and hematological abnormalities due to declining physiological functions, chronic diseases and multi-drug sharing. Hepatic and renal toxicity, cardiovascular events and hematological abnormalities. When using pazopanib in elderly patients, the dose should be appropriately adjusted, the monitoring interval should be extended, and attention should be paid to quality of life and management of complications.

4.Populations at risk for drug interactions

Pazopanib is mainly metabolized by CYP3A4, and co-administration with potent CYP3A4 inhibitors or inducers may cause the blood concentration to increase or decrease, increase toxicity or reduce efficacy. Patients who use multiple drugs or Chinese medicines need to pay special attention to drug interactions and adjust the dosage or change medications if necessary.

4. Clinical medication recommendations and safety management

Before using pazopanib, the patient's liver and kidney function, cardiovascular condition, blood pressure and medication history should be comprehensively assessed to identify contraindications and high-risk groups. Liver function, kidney function, electrolytes, blood pressure and electrocardiogram should be monitored regularly during treatment. Once abnormalities are found, the dosage should be adjusted or the medication should be suspended. At the same time, patients should be informed to pay attention to bleeding, rash, fatigue and gastrointestinal symptoms, and to seek medical attention immediately in case of serious adverse reactions. Through strict individualized management, risks can be minimized while ensuring efficacy.

Pazopanib has important clinical value in the treatment of advanced renal cell carcinoma and soft tissue sarcoma, but its adverse reactions and potential risks cannot be ignored. Clarifying contraindications, identifying high-risk groups, individualized assessment and close monitoring are the keys to safe medication use. Only when used under scientific management can the efficacy be maximized while ensuring patient safety.

Reference materials:https://www.drugs.com/